Progenra, Inc.
Biotechnology ResearchPennsylvania, United States11-50 Employees
Progenra, Inc. is a biotechnology research company based in Malvern, Pennsylvania, focusing on the discovery and development of ubiquitin-based therapies using PROTACs to target and degrade disease-related proteins. Its approach emphasizes the catalytic action of PROTACs and potential advantages over traditional inhibitors, with internal programs spanning biochemical and biological target validation alongside medicinal chemistry and lead optimization. The firm aims to advance a new class of PROTAC molecules through preclinical development, supported by its in-house discovery platform. The organization operates in a specialized segment of proteostasis-based therapy, addressing unmet needs in targeted protein degradation for therapeutic applications. While relatively small in size, Progenra maintains an active research footprint and has engaged in collaborations reflected in its scientific advisory activities, including the appointment of external experts. A recent development involves continued progress in its drug discovery efforts for PARKIN activators, aligning with its broader focus on novel modulators of protein homeostasis.
1-888-653-2347 
support@leadiq.com 
